| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 0.44 | 12.0% |
| Total Income | 0.44 | 12.0% |
| Expenditure | 10.78 | 101.5% |
| PBT | -10.79 | 123.9% |
| Net Profit | -10.79 | 123.4% |
| OPM | — | |
| NPM | — | |
| EPS | -6.70 | 1356.5% |
Lifeward Reports Q1 2026 Revenue of $3.9 Million
15 May 2026 · 15 May, 5:32 pm
Summary
Lifeward Ltd. reported a revenue of $3.9 million for the first quarter of 2026, a 22% decrease compared to the $5.0 million reported in the same period of 2025. The gross margin decreased to 34.2% from 42.2% year-over-year, primarily due to lower production volumes and higher tariffs. Operating expenses increased to $11.7 million, driven by a one-time R&D expense related to the Oratech transaction. The company's cash position improved, with $11.4 million in cash and cash equivalents as of March 31, 2026, driven by financing and the Oratech acquisition.
Key Highlights
- 1
Lifeward's revenue was $3.9 million in the first quarter of 2026, compared to $5.0 million in the first quarter of 2025, representing a decrease of approximately 22%.
- 2
ReWalk Personal exoskeleton sales increased by 11% to $1.6 million in the first quarter of 2026 compared to the same period in 2025.
- 3
Gross margin was 34.2% during the first quarter of 2026, compared to 42.2% in the first quarter of 2025.
- 4
Total operating expenses in the first quarter of 2026 were $11.7 million, compared to $7.0 million in the first quarter of 2025.
- 5
The company's operating cash burn reduced by 33% year-over-year, reflecting improved operational efficiencies and working capital management.
- 6
Net loss was $10.8 million, or $6.70 per share, in the first quarter of 2026, compared to $4.8 million, or $5.53 per share, in the first quarter of 2025.
- 7
Lifeward had $11.4 million in unrestricted cash and cash equivalents as of March 31, 2026, compared to $2.2 million as of December 31, 2025.
Management Comments
Mark Grant
“During the first quarter, we significantly strengthened Lifeward’s strategic and financial position through the successful closing of our strategic transaction and financing, marking an important milestone in our evolution,” “With the additional capital added to our balance sheet, the acquisition of Oratech and its Protein Oral Delivery platform, and continued improvements in operating efficiency and cash utilization, we believe Lifeward is now better positioned on its path toward profitability. As we continue to build and grow our solid foundation in neurorehabilitation medtech, our shareholders also have a meaningful opportunity through our Protein Oral Delivery biomed platform.”
Informational and educational content only. Not investment advice.